A Clinical AI Change Control Board operationalizes the discipline described in FDA predetermined change control plan (PCCP) guidance and applies it consistently across regulated and non-regulated clinical AI systems.
Definition and scope
A Clinical AI Change Control Board is a cross-disciplinary governance body that reviews and approves changes to clinical AI models, prompts, tools, and data integrations before they reach production. Its scope covers the change surface that affects clinical behavior: model updates, prompt revisions, tool wiring, and data integrations that can alter outputs or risk profile.
Regulatory grounding
Board practice is informed by FDA predetermined change control plan (PCCP) guidance and Good Machine Learning Practice (GMLP) principles for AI/ML-based software as a medical device (SaMD). Where the system is a regulated SaMD, change documentation should be structured to match PCCP components: description of the modification, the modification protocol, and an impact assessment.
Important distinction: “Clinical AI Change Control Board” is not a formal FDA or standards-body term. It is an organizational pattern used to apply PCCP and GMLP discipline in day-to-day operations, including for systems that are not themselves regulated SaMD.
Decision rights and what requires board review
The board owns approval for changes that can affect clinical performance, safety, or compliance posture. Typical categories include model retrains, prompt updates, and tool or data integrations. Defining these categories in advance allows differentiated review paths so routine changes do not consume full board cycles while higher-impact changes receive multidisciplinary scrutiny.
Board-level review vs. routine operational change
Not every edit should wait for a full board session. Effective programs separate board-level decisions from routine operational change by pre-agreed category rules. Lower-risk, well-characterized updates can follow a lighter path; material changes to model behavior, external tools, or data sources remain at board level. This separation keeps governance credible without blocking normal delivery.
How runtime enforcement supports the board
Approval alone does not guarantee that production matches intent. Runtime policy enforcement and audit logging close that gap: they confirm that only board-approved changes reach production and that unapproved drift is visible and actionable. Escalation and rollback procedures should be defined in advance for cases where post-deployment monitoring detects drift or an unauthorized change.
Composing and operating an effective board
Composition and operating rhythm determine whether the board is a durable control or a paper process. Multidisciplinary representation (clinical, technical, regulatory or quality, and security) aligns with GMLP guiding principles. Technical integration of approval checkpoints into MLOps or CI/CD gates ensures decisions are enforced before deployment, not only documented afterward.
- Define change categories in advance (model retrain, prompt update, tool or data integration) with differentiated review paths, so routine changes do not require full board cycles.
- Compose the board with multidisciplinary representation, including clinical, technical, regulatory or quality, and security stakeholders, consistent with GMLP guiding principles.
- Integrate board approval checkpoints into MLOps or CI/CD pipeline gates so approvals are enforced technically before deployment, not only documented after the fact.
- Where the system is a regulated SaMD, structure change documentation to match PCCP components: description of the modification, the modification protocol, and an impact assessment.
- Define escalation and rollback procedures in advance for cases where post-deployment monitoring detects drift or an unauthorized change.